# ASND catalysts: Ascendis Pharma A/S PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/asnd/catalysts

> Ascendis Pharma A/S (ASND) has 13 upcoming catalysts. The next is the TransCon (transcon) topline data readout, Q3 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ASND?

Ascendis Pharma A/S (ASND) has 13 upcoming catalysts. The next is the TransCon (transcon) topline data readout, Q3 2027. Press release filed with the SEC (EX-99): "<2 years showing TransCon CNP stabilized or improved foramen magnum stenosis, and increased linear growth; topline pivotal data expected Q3 2027" [Calendar and source filings](https://sec-api.dev/companies/asnd/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-456989, https://www.sec.gov/Archives/edgar/data/1612042/000119312526456989/d80569dex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/asnd/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Ascendis Pharma A/S |
| Ticker | ASND (Nasdaq) |
| SEC CIK | 1612042 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/asnd |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2022 | [TransCon (transcon) topline data readout](https://sec-api.dev/pdufa/transcon) | ASND |  | completed, met | "In March 2022, we announced that top-line data from the randomized, double-blind, placebo-controlled portion of the Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism demonstrated statistically significant higher proportion of participants treated with TransCon PTH achieved the primary multi-component endpoint compared to placebo." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312525277622/asnd-20250930.htm)) |
| Apr 2023 | [TransCon (transcon) complete response letter (CRL)](https://sec-api.dev/pdufa/transcon) | ASND |  | completed, complete response letter | "For example, in April 2023 the FDA issued a Complete Response Letter in response to our original NDA submission for TransCon PTH, in which the FDA cited concerns related to the manufacturing control strategy for variability of delivered dose in the TransCon PTH drug/device combination product." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm)) |
| Dec 2023 | [Ascendis Pharma A/S topline data readout](https://sec-api.dev/companies/asnd/catalysts) | ASND |  | completed, positive | "In December 2023, we announced positive top-line results from foresiGHt." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000095017025061850/asnd-20250331.htm)) |
| Aug 2024 | [TransCon (transcon) FDA approval](https://sec-api.dev/pdufa/transcon) | ASND | hypoparathyroidism in adults | completed, approved | "In August 2024, the U.S. FDA approved TransCon PTH for the treatment of hypoparathyroidism in adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000095017024127079/asnd-20240930.htm)) |
| Aug 2024 | [YORVIPATH (palopegteriparatide) FDA approval](https://sec-api.dev/pdufa/palopegteriparatide) | ASND | hypoparathyroidism in adults | completed, approved | "In August 2024, the FDA approved YORVIPATH (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000161204226000005/asnd-20260331.htm)) |
| Q4 2024 | [Ascendis Pharma A/S topline data readout](https://sec-api.dev/companies/asnd/catalysts) | ASND |  | scheduled | "Topline results from New InsiGHTS are expected in the fourth quarter of 2024." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000095017024127079/asnd-20240930.htm)) |
| Q4 2024 | [Ascendis Pharma A/S topline data readout](https://sec-api.dev/companies/asnd/catalysts) | ASND |  | scheduled | "Topline results from Phase 2 New InsiGHTS Trial in Turner syndrome expected in the fourth quarter of 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312524258608/d827238dex991.htm)) |
| Dec 2024 | [TransCon (transcon) NDA/BLA submission](https://sec-api.dev/pdufa/transcon) | ASND | in Japan with hypoparathyroidism | completed | "In December 2024, submitted a J-NDA to the Japanese medical authorities for TransCon PTH for the treatment of adults in Japan with hypoparathyroidism" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312525004905/d923527dex991.htm)) |
| Dec 2024 | [Ascendis Pharma A/S NDA/BLA acceptance](https://sec-api.dev/companies/asnd/catalysts) | ASND |  | completed | "In December 2024, we announced the FDA accepted the sBLA for review and set a Prescription Drug User Fee Act ("PDUFA") goal date of July 27, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000095017025061850/asnd-20250331.htm)) |
| Dec 2024 | [Ascendis Pharma A/S topline data readout](https://sec-api.dev/companies/asnd/catalysts) | ASND |  | completed, positive | "In December 2024, we announced positive Week 26 topline results from the Phase 2 New InsiGHTS Trial." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000161204226000024/asnd-20260930.htm)) |
| Q1 2025 | [YUVIWEL® (navepegritide) NDA/BLA submission](https://sec-api.dev/pdufa/navepegritide) | ASND |  | scheduled | "Following pre-NDA meeting with FDA, plan to submit New Drug Application (NDA) for the treatment of children with achondroplasia during the first quarter of 2025, and submit Marketing Authorisation Application to the European Medicines Agency during the third quarter of 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312525004900/d906180d6k.htm)) |
| March 31, 2025 | [YUVIWEL® (navepegritide) NDA/BLA acceptance](https://sec-api.dev/pdufa/navepegritide) | ASND | children with achondroplasia | completed | "We submitted a New Drug Application ("NDA") for the treatment of children with achondroplasia on March 31, 2025 and the FDA has accepted for priority review our NDA for TransCon CNP (navepegritide)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312526063954/d112586dex992.htm)) |
| March 31, 2025 | [YUVIWEL® (navepegritide) NDA/BLA submission](https://sec-api.dev/pdufa/navepegritide) | ASND | children with achondroplasia | completed | "On March 31, 2025, the Company announced that it has submitted its New Drug Application to the U.S. Food & Drug Administration for TransCon CNP (navepegritide) for the treatment of children with achondroplasia." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312525068722/d923652d6k.htm)) |
| Q2 2025 | [TransCon (transcon) topline data readout](https://sec-api.dev/pdufa/transcon) | ASND | achondroplasia | scheduled | " Topline COACH combination trial (TransCon CNP + TransCon hGH) data expected in Q2 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312525110062/d795154dex991.htm)) |
| Q2 2025 | [Ascendis Pharma A/S topline data readout](https://sec-api.dev/companies/asnd/catalysts) | ASND | achondroplasia | scheduled | "Topline Week 26 results from our Phase 2 COACH Trial in children with achondroplasia are expected in the second quarter of 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000095017025061850/asnd-20250331.htm)) |
| Q2 2025 | [Ascendis Pharma A/S topline data readout](https://sec-api.dev/companies/asnd/catalysts) | ASND |  | scheduled | "Week 26 top-line data from the COACH Trial are expected in the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312525103766/d75062dex992.htm)) |
| April 29, 2025 | [Ascendis Pharma A/S NDA/BLA acceptance](https://sec-api.dev/companies/asnd/catalysts) | ASND |  | completed | "In December, we announced the FDA accepted the sBLA for review and set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312525103766/d75062dex992.htm)) |
| Jul 2025 | [SKYTROFA (lonapegsomatropin) FDA approval](https://sec-api.dev/pdufa/lonapegsomatropin) | ASND | growth hormone deficiency | completed, approved | "In July 2025, we announced that the FDA had approved SKYTROFA (lonapegsomatropin-tcgd; developed as TransCon hGH) for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD), a rare disorder resulting from decreased or total loss of growth hormone production." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000161204226000005/asnd-20260331.htm)) |
| July 27, 2025 | [SKYTROFA (lonapegsomatropin) PDUFA date](https://sec-api.dev/pdufa/lonapegsomatropin) | ASND | with GHD | scheduled | "SKYTROFA - Approved for pediatric growth hormone deficiency (GHD) 2 - Full-year 2024 SKYTROFA revenue expected to be ~€202 million , excluding sales deductions related to prior years - sBLA submitted for the treatment of adults with GHD, with a PDUFA goal date of July 27, 2025 ® 1" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312525004905/d923527dex991.htm)) |
| Q4 2025 | [Ascendis Pharma A/S interim data readout](https://sec-api.dev/companies/asnd/catalysts) | ASND |  | scheduled | "The interim analysis will be followed by Week 52 data, expected in Q4 2025, and Ascendis plans to initiate a Phase 3 trial in Q4 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312525137801/d22089d6k.htm)) |
| November 30, 2025 | [YUVIWEL® (navepegritide) PDUFA date](https://sec-api.dev/pdufa/navepegritide) | ASND | children with achondroplasia | delayed | "TransCon® CNP (navepegritide) under FDA Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312525277532/d88973dex991.htm)) |
| February 27, 2026 | [YUVIWEL® (navepegritide) FDA approval](https://sec-api.dev/pdufa/navepegritide) | ASND |  | completed, approved | "Yuviwel \| navepegritide \| 2/27/2026 \| To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| February 28, 2026 | [TransCon (transcon) PDUFA date](https://sec-api.dev/pdufa/transcon) | ASND |  | scheduled | "- TransCon® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312526046736/d73635dex991.htm)) |
| March 17, 2026 | [SKYTROFA (lonapegsomatropin) topline data readout](https://sec-api.dev/pdufa/lonapegsomatropin) | ASND |  | completed, positive | "On March 17, 2026, the Company announced positive Week 52 topline results from New InsiGHTS, its Phase 2 randomized, open-label, active-controlled trial in the U.S. investigating the safety, tolerability, and efficacy of once-weekly TransCon hGH (lonapegsomatropin; U.S. FDA-approved for pediatric and adult growth hormone deficiency (GHD)" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312526110751/d95087d6k.htm)) |
| June 30, 2026 | [YUVIWEL® (navepegritide) FDA approval](https://sec-api.dev/pdufa/navepegritide) | ASND |  | completed, approved | "Further, the six months ended June 30, 2026 included a reversal (income) of prior period write-downs related to pre-launch inventories for Growth Disorders of €10.9 million due to the U.S. FDA approval of YUVIWEL." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000161204226000016/asnd-20260630.htm)) |
| September 30, 2026 | [YUVIWEL® (navepegritide) FDA approval](https://sec-api.dev/pdufa/navepegritide) | ASND |  | completed, approved | "Further, the nine months ended September 30, 2026 included the reversal (income) of prior-period write-downs of €10.9 million related to pre-launch inventories for Growth Disorders due to the U.S. FDA approval of YUVIWEL." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000161204226000024/asnd-20260930.htm)) |
| Q3 2027 | [TransCon (transcon) topline data readout](https://sec-api.dev/pdufa/transcon) | ASND |  | scheduled | "<2 years showing TransCon CNP stabilized or improved foramen magnum stenosis, and increased linear growth; topline pivotal data expected Q3 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312526456989/d80569dex991.htm)) |
| August 2027 | [YORVIPATH (palopegteriparatide) primary completion](https://sec-api.dev/pdufa/palopegteriparatide) | ASND | Hypoparathyroidism | scheduled | "NCT07706764 (A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07706764)) |
| Aug to Nov 2027 | [YORVIPATH (palopegteriparatide) topline data readout](https://sec-api.dev/pdufa/palopegteriparatide) | ASND | Hypoparathyroidism | scheduled | "NCT07706764 (A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07706764)) |
| September 2027 | [YUVIWEL® (navepegritide) primary completion](https://sec-api.dev/pdufa/navepegritide) | ASND | Achondroplasia | scheduled | "NCT06732895 (A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06732895)) |
| Sep to Dec 2027 | [YUVIWEL® (navepegritide) topline data readout](https://sec-api.dev/pdufa/navepegritide) | ASND | Achondroplasia | scheduled | "NCT06732895 (A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06732895)) |
| December 2027 | [YUVIWEL® (navepegritide) primary completion](https://sec-api.dev/pdufa/navepegritide) | ASND | Achondroplasia | scheduled | "NCT06079398 (A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079398)) |
| Dec 2027 to Mar 2028 | [YUVIWEL® (navepegritide) topline data readout](https://sec-api.dev/pdufa/navepegritide) | ASND | Achondroplasia | scheduled | "NCT06079398 (A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079398)) |
| February 2028 | [Lonapegsomatropin [skytrofa®] primary completion](https://sec-api.dev/pdufa/lonapegsomatropin-skytrofa) | ASND | Turner Syndrome; Short Stature Homeobox Gene Mutation; Idiopathic Short Stature | scheduled | "NCT07221851 (Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221851)) |
| Feb to May 2028 | [Lonapegsomatropin [skytrofa®] topline data readout](https://sec-api.dev/pdufa/lonapegsomatropin-skytrofa) | ASND | Turner Syndrome; Short Stature Homeobox Gene Mutation; Idiopathic Short Stature | scheduled | "NCT07221851 (Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221851)) |
| September 2028 | [Dual therapy with navepegritide and lonapegsomatropin primary completion](https://sec-api.dev/pdufa/dual-therapy-with-navepegritide-and-lonapegsomatropin) | ASND | Achondroplasia | scheduled | "NCT07924059 (Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07924059)) |
| Sep to Dec 2028 | [Dual therapy with navepegritide and lonapegsomatropin topline data readout](https://sec-api.dev/pdufa/dual-therapy-with-navepegritide-and-lonapegsomatropin) | ASND | Achondroplasia | scheduled | "NCT07924059 (Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07924059)) |
| October 2028 | [YUVIWEL® (navepegritide) primary completion](https://sec-api.dev/pdufa/navepegritide) | ASND | Hypochondroplasia | scheduled | "NCT07917143 (A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With Hypochondroplasia): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07917143)) |
| Oct 2028 to Jan 2029 | [YUVIWEL® (navepegritide) topline data readout](https://sec-api.dev/pdufa/navepegritide) | ASND | Hypochondroplasia | scheduled | "NCT07917143 (A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With Hypochondroplasia): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07917143)) |

## Drugs

- [Dual therapy with navepegritide and lonapegsomatropin](https://sec-api.dev/pdufa/dual-therapy-with-navepegritide-and-lonapegsomatropin): Achondroplasia
- [SKYTROFA (lonapegsomatropin)](https://sec-api.dev/pdufa/lonapegsomatropin): growth hormone deficiency, with ghd
- [Lonapegsomatropin [skytrofa®]](https://sec-api.dev/pdufa/lonapegsomatropin-skytrofa): Turner Syndrome
- [YUVIWEL® (navepegritide)](https://sec-api.dev/pdufa/navepegritide): children with achondroplasia, children with achondroplasia, prescription drug user fee act, Achondroplasia, Hypochondroplasia
- [YORVIPATH (palopegteriparatide)](https://sec-api.dev/pdufa/palopegteriparatide): hypoparathyroidism in adults, Hypoparathyroidism
- [TransCon (transcon)](https://sec-api.dev/pdufa/transcon): achondroplasia, in japan with hypoparathyroidism, hypoparathyroidism in adults

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/asnd/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ASND catalysts: Ascendis Pharma A/S PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/asnd/catalysts

```bibtex
@misc{secapidev_companies_asnd_catalysts_20261116,
  title        = {ASND catalysts: Ascendis Pharma A/S PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/asnd/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_asnd_catalysts_20261116","title":"ASND catalysts: Ascendis Pharma A/S PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/asnd/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
